A detailed history of Barclays PLC transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Barclays PLC holds 325,953 shares of CORT stock, worth $16.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
325,953
Previous 325,953 -0.0%
Holding current value
$16.8 Million
Previous $15.1 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$29.51 - $46.26 $1.82 Million - $2.85 Million
61,510 Added 23.26%
325,953 $15.1 Million
Q2 2024

Aug 14, 2024

SELL
$22.21 - $34.48 $239,890 - $372,418
-10,801 Reduced 3.92%
264,443 $8.59 Million
Q1 2024

May 15, 2024

BUY
$21.1 - $27.46 $1.98 Million - $2.57 Million
93,693 Added 51.61%
275,244 $6.93 Million
Q4 2023

Feb 15, 2024

BUY
$24.82 - $32.88 $2.67 Million - $3.54 Million
107,565 Added 145.39%
181,551 $5.9 Million
Q3 2023

Nov 07, 2023

BUY
$21.97 - $33.8 $50,509 - $77,706
2,299 Added 3.21%
73,986 $2.02 Million
Q2 2023

Aug 03, 2023

SELL
$21.44 - $25.15 $306,034 - $358,991
-14,274 Reduced 16.61%
71,687 $1.6 Million
Q1 2023

May 04, 2023

BUY
$19.2 - $24.47 $8,198 - $10,448
427 Added 0.5%
85,961 $1.86 Million
Q4 2022

Feb 13, 2023

BUY
$19.95 - $29.96 $38,204 - $57,373
1,915 Added 2.29%
85,534 $1.74 Million
Q3 2022

Nov 03, 2022

BUY
$24.7 - $29.12 $169,516 - $199,850
6,863 Added 8.94%
83,619 $2.15 Million
Q2 2022

Aug 12, 2022

SELL
$17.33 - $25.3 $618,386 - $902,779
-35,683 Reduced 31.74%
76,756 $1.83 Million
Q1 2022

May 16, 2022

SELL
$16.53 - $25.21 $1 Million - $1.53 Million
-60,638 Reduced 35.04%
112,439 $2.53 Million
Q4 2021

Feb 14, 2022

BUY
$17.1 - $23.34 $151,317 - $206,535
8,849 Added 5.39%
173,077 $3.43 Million
Q3 2021

Nov 09, 2021

BUY
$19.68 - $22.53 $1.79 Million - $2.05 Million
91,093 Added 124.55%
164,228 $3.23 Million
Q2 2021

Aug 13, 2021

SELL
$19.97 - $24.43 $2.14 Million - $2.61 Million
-106,929 Reduced 59.38%
73,135 $1.61 Million
Q1 2021

May 13, 2021

SELL
$23.49 - $30.56 $746,794 - $971,563
-31,792 Reduced 15.01%
180,064 $4.28 Million
Q4 2020

Feb 11, 2021

SELL
$16.78 - $27.3 $1.06 Million - $1.73 Million
-63,239 Reduced 22.99%
211,856 $5.54 Million
Q3 2020

Nov 12, 2020

BUY
$12.46 - $19.98 $175,162 - $280,878
14,058 Added 5.39%
275,095 $4.79 Million
Q2 2020

Aug 12, 2020

BUY
$11.0 - $18.26 $257,730 - $427,831
23,430 Added 9.86%
261,037 $4.39 Million
Q1 2020

May 13, 2020

BUY
$10.11 - $14.04 $280,410 - $389,413
27,736 Added 13.22%
237,607 $2.83 Million
Q4 2019

Feb 10, 2020

BUY
$12.06 - $16.96 $1.24 Million - $1.74 Million
102,558 Added 95.57%
209,871 $2.54 Million
Q3 2019

Nov 14, 2019

SELL
$10.41 - $14.66 $69,871 - $98,397
-6,712 Reduced 5.89%
107,313 $1.52 Million
Q2 2019

Aug 14, 2019

BUY
$9.78 - $12.76 $130,396 - $170,129
13,333 Added 13.24%
114,025 $1.27 Million
Q1 2019

May 15, 2019

BUY
$10.03 - $15.71 $491,159 - $769,302
48,969 Added 94.68%
100,692 $1.18 Million
Q4 2018

Feb 14, 2019

SELL
$11.29 - $17.19 $814,731 - $1.24 Million
-72,164 Reduced 58.25%
51,723 $691,000
Q3 2018

Nov 14, 2018

BUY
$12.27 - $15.65 $1.05 Million - $1.34 Million
85,571 Added 223.33%
123,887 $1.74 Million
Q2 2018

Aug 14, 2018

BUY
$15.3 - $19.69 $148,333 - $190,894
9,695 Added 33.87%
38,316 $602,000
Q1 2018

May 15, 2018

SELL
$14.59 - $25.5 $597,548 - $1.04 Million
-40,956 Reduced 58.86%
28,621 $470,000
Q4 2017

Feb 14, 2018

SELL
$15.77 - $20.72 $266,481 - $350,126
-16,898 Reduced 19.54%
69,577 $1.26 Million
Q3 2017

Nov 14, 2017

BUY
$12.3 - $19.3 $1.06 Million - $1.67 Million
86,475
86,475 $1.67 Million

Others Institutions Holding CORT

About CORCEPT THERAPEUTICS INC


  • Ticker CORT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,105,000
  • Market Cap $5.51B
  • Description
  • Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...
More about CORT
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.